Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Animal Health

Bovine TB is emotionally and economically devastating. 289,000 cattle have been slaughted in the UK in the last 10 years and compensation cost the tax payer £34m in 2018/19. There must be an alternative to 'test and cull'.

Loading...

Mycobacteria are responsible for a number of diseases including: Bovine tuberculosis, a chronic, infectious disease caused by Mycobacterium bovis (M.bovis), it can infect humans, livestock, wildlife, and exotic species and Johne's Disease or ParaTB which is a wasting disease in ruminants.

Unlike other technologies, the Actiphage test does not measure an immune response, but specifically detects the DNA extracted from live Mycobacteria present in circulating blood as a marker of disease.

PBD Biotech is currently in the process of verifying the Actiphage test for the detection of Mycobacterium bovis (bovine TB) in cattle blood.

Certification by the World Organisation for Animal Health (OIE) is required for a bTB diagnostics to become an internationally recognised diagnostic, however, Actiphage can be used as a diagnostic in England and Wales for disease management in areas of chronic disease breakdown.

These restrictions are not in place for Johne's Disease also known as MAP and PBD Biotech has launched a commercial Johne's Disease testing service.

Testing in over 20 species

However, Actiphage is able to detect most other mycobacterial species and has been successfully applied to samples from multiple animal species.

PBD Biotech has proof-of-concept data that the test can be applied to over 20 species, including humans, and remain open to collaboration with researchers and regulators across the globe who want to advance the science and understanding of these devastating diseases.

Read more about the testing for Johne's Disease (ParaTB), MAP and bovine TB

Actiphage and bovine TB.

Actiphage and Johne's Disease or MAP

Actiphage and exotic species

MAP testing for milk quality assurance

To use the Johne's Testing Service for blood or bulk milk do get in touch

If you are interested in using Actiphage for research use the order form or contact us

Suspending Johne’s Disease testing service from Jan 2023

PBD Biotech has announced that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service (from January 2023) More information.

Please contact us if you would like to discuss this further.

Related content

Loading...

PBD Biotech closes seed investment round

August 24, 2017
PBD Biotech Ltd is delighted to announce that it has successfully completed an over-subscribed seed investment round composed of angel investment from Cambridge Agritech Ltd and Anglia Capital Group.

PBD Biotech closes seed investment round

August 24, 2017
PBD Biotech Ltd is delighted to announce that it has successfully completed an over-subscribed seed investment round composed of angel...

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!